Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)

Purpose. To assess the clinical results in terms of local control, toxicity, failure pattern and toxicity of SBRT in oligometastatic patients with inoperable lung metastases. Methods. Forty-four patients were treated (53 metastases). Dose regimen: 5 × 12 Gy (66 %), 8 × 7.5 Gy (20.8 %) and 10 × 5 Gy (13.2 %). Response was assessed using PET/CT at 6 months after SBRT. Results. Local control at 1 and 2 years was 86.7 %. Seventy-five percent of local failures had received a BED <105 Gy. After a median follow-up of 13.3 months, 25 % experienced distant progression. Overall survival at 1 and 2 years was 86.7 and 60.4 %, and cancer-specific survival was 95.3 and 75.2 %, respectively. Grade 2 toxicity was 6.8 %. There was no grade 3–4 toxicity. Conclusion. SBRT is effective and safe. The main failure pattern is distant progression. The selection of patients with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources (AU)

No disponible

Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT).

PURPOSE: To assess the clinical results in terms of local control, toxicity, failure pattern and toxicity of SBRT in oligometastatic patients with inoperable lung metastases. METHODS: Forty-four patients were treated (53 metastases). Dose regimen: 5 × 12 Gy (66 %), 8 × 7.5 Gy (20.8 %) and 10 × 5 Gy (13.2 %). Response was assessed using PET/CT at 6 months after SBRT. RESULTS: Local control at 1 and 2 years was 86.7 %. Seventy-five percent of local failures had received a BED <105 Gy. After a median follow-up of 13.3 months, 25 % experienced distant progression. Overall survival at 1 and 2 years was 86.7 and 60.4 %, and cancer-specific survival was 95.3 and 75.2 %, respectively. Grade 2 toxicity was 6.8 %. There was no grade 3-4 toxicity. CONCLUSION: SBRT is effective and safe. The main failure pattern is distant progression. The selection of patients with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources.

Radiotherapy in rectal cancer: development, adequacy and radiotherapy utilisation rate. A comparative analysis with the most frequent tumour sites

INTRODUCTION: Radiotherapy is a basic weapon in the local treatment of multiple solid tumors. The radiotherapy activity has been evaluated in our centre during the past eleven years. The study focused on rectal cancer. MATERIALS AND METHODS: This is a descriptive study of all radiotherapy procedures performed between January 1998 and December 2008. It quantifies the workload of each pathology treated, the rate of irradiation and its adequacy with optimal rates of irradiation according to the best available scientific evidence. RESULTS: We quantified 9,622 external radiotherapy procedures of which 6,009 were associated with the five pathologies that involved the highest workloads. Of these, 905 were performed in rectal cancer. The workloads due to cancers of the breast, prostate, lung, gynaecological pathologies and rectal cancers were 23.2%, 11.8%, 11.6%, 6.3% and 9.3% respectively. The real "radiotherapy utilisation rates" of these pathologies were 62%, 20.2%, 34.3%, 21% and 64% respectively, while the "rates of adequacy" were 74.7%, 33.6%, 45.1%, 60% and 104.8%. CONCLUSIONS: The "radiotherapy utilisation rate" for rectal cancer was equivalent to the estimated optimum rate as defined on the basis of reference groups. The therapy utilised developed chronologically in parallel with the available scientific evidence. The radiotherapy utilisation rates for breast and prostate cancer gradually increased, with a tendency to reach optimal rates. Radiotherapy as a treatment for lung cancer was underutilised. In global terms, the rate of utilisation of radiation therapy was low, although it displayed a tendency to increase (AU)

Equipamiento y perspectivas de futuro de la Radioterapia Oncológica. Situación española / Equipment and Outlook for Radiotherapy Oncology. The situation in Spain

Durante la última década la radioterapia ha presentado un desarrollo tecnológico y radiobiológico exponencial. La aplicación clínica del avance en conocimientos biológicos es todavía escasa pero se augura un gran potencial de mejora en resultados terapéuticos. La evolución tecnológica está consiguiendo optimizar la distribución de la dosis en los volúmenes irradiados y conseguir tratamientos menos tóxicos. Hasta la fecha se desconoce la exacta repercusión del mejor control local tumoral sobre la supervivencia de la enfermedad. El nivel de desarrollo tecnológico español era escaso en 1999. La dotación actual es sin duda superior en parte fruto de la evidente infradotación explicita en el inventario practicado por la Asociación Española de Radioterapia y Oncología en los años 1999-2000 y cuyos datos se resumen (AU)

The authors of this paper describe the advances Radiotherapy has brought to this country over the last decade. They discuss the technological developments which are allowing radiation volume dosing to be optimized, leading to less toxic treatment (AU)

Ameloblastomas maxilares: a propósito de un caso clínico y revisiónde la literatura / Maxillary ameloblastoma: about a clinical case and review of the literature

- Propósito: se revisan los datos epidemiológicos, clínicos, anatomopatológicos y los procedimientos diagnósticos y terapéuticos de los ameloblastomas maxilares.- Material y métodos: se presenta un caso de ameloblastoma de maxilar superior en una mujer de 36 años.- Resultados: se realizó tratamiento con radioterapia postoperatoria tras cirugía radical, dado que se trataba de una lesión extensa en una paciente joven. Tras un seguimiento de 5 años y medio la paciente se encuentra libre de enfermedad.- Conclusiones: se describe el comportamiento de este tumor así como su tratamiento (AU)